Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3909 - The SP142 PD-L1 IHC assay for atezolizumab (atezo) reflects pre-existing immune status in NSCLC and correlates with PD-L1 mRNA

Date

10 Oct 2016

Session

Poster display

Presenters

James Williams

Citation

Annals of Oncology (2016) 27 (6): 401-406. 10.1093/annonc/mdw380

Authors

J. Williams1, M. Kowanetz2, H. Koeppen3, Z. Boyd4, E.E. Kadel III3, D. Smith3, M. McCleland3, W. Zou5, P.S. Hegde6

Author affiliations

  • 1 Diagnostic Lead, Genentech, Inc, 94080 - South San Francisco/US
  • 2 Oncology Biomarker Development, Genentech, Inc, 94080 - South San Francisco/AM
  • 3 Oncology Biomarker Development, Genentech, Inc., 94080 - South San Francisco/US
  • 4 Diagnostic Development, Genentech, Inc, 94080 - South San Francisco/US
  • 5 Oncology Biomarker, Genentech, Inc., South San Francisco/US
  • 6 Oncology Biomarker Department, Genentech, Inc., South San Francisco/US
More

Resources

Abstract 3909

Background

PD-L1 expression as measured by the SP142 PD-L1 IHC assay is associated with improved efficacy with atezo in patients with NSCLC, including overall survival. In capturing PD-L1 on both tumor cells (TC) and tumor-infiltrating immune cells (IC), this assay is able to determine preexisting immune status, underscoring the predictive value of PD-L1 IHC. In this study, we further investigated intratumoral immune infiltration status by measuring T effector (Teff) gene signature and correlated PD-L1 mRNA expression with SP142 PD-L1 IHC.

Methods

Using the SP142 IHC assay, procured samples from NSCLC tumors were scored according to the percent of TC expressing PD-L1 (TC0 

Results

In 86 NSCLC specimens, mRNA levels for PD-L1 increased incrementally with higher PD-L1 IHC status, from 0 median expression for TC0 and IC0 tumors to 3.14 median expression for TC3 or IC3 tumors. A similar trend was seen for the Teff signature, with values increasing from 0 to 1.65 median expression with increasing IHC cutoffs (Table).

Conclusions

Results from the SP142 PD-L1 IHC assay associates with PD-L1 and Teff mRNA transcripts, reflecting pre-existing immunity associated with adaptive PD-L1 expression on IC as well as intrinsic PD-L1 expression on TC in NSCLC, thus providing an independent orthogonal correlation of IHC to gene expression. The value of mRNA gene expression as a predictive marker of efficacy for atezo in NSCLC is being studied in ongoing randomized trials of atezo.

PD-L1 IHC vs PD-L1 mRNA and T effector gene signature

PD-L1 IHC PD-L1 mRNA T Effectora
n Medianb expression 95% CI n Medianb expression 95% CI
TC0 and IC0 46 0 −0.22, 0.36 46 0 −0.39, 0.16
TC1 or IC1 22 0.89 0.53, 1.66 22 0.73 0.25, 0.95
TC2 or IC2 11 2.66 2.49, 2.85 11 1.53 0.55, 1.57
TC3 or IC3 7 3.14 1.4, 4.29 7 1.65 0.46, 1.95

a Includes CD8A, GZMA, GZMB, EOMES, CXCL9, CXCL10, TBX21. b Median expressions are log scale expression (−ΔCT) relative to the median of TC0 and IC0 group. Larger values indicate higher expression.

Clinical trial identification

Not applicable.

Legal entity responsible for the study

F. Hoffmann-La Roche, Ltd.

Funding

F. Hoffmann-La Roche, Ltd.

Disclosure

J. Williams, M. Kowanetz, H. Koeppen, Z. Boyd, E.E. Kadel III, D. Smith, M. McCleland, W. Zou, P.S. Hegde: Employee of Genentech.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings